ID SEM3A_HUMAN Reviewed; 771 AA. AC Q14563; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 01-NOV-1996, sequence version 1. DT 27-MAR-2024, entry version 203. DE RecName: Full=Semaphorin-3A; DE AltName: Full=Semaphorin III; DE Short=Sema III; DE Flags: Precursor; GN Name=SEMA3A; Synonyms=SEMAD; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Fetal brain; RX PubMed=8269517; DOI=10.1016/0092-8674(93)90625-z; RA Kolodkin A.L., Matthes D.J., Goodman C.S.; RT "The semaphorin genes encode a family of transmembrane and secreted growth RT cone guidance molecules."; RL Cell 75:1389-1399(1993). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=12853948; DOI=10.1038/nature01782; RA Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H., RA Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K., RA Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A., RA Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H., RA Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A., RA Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P., RA Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M., RA Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S., RA Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., RA Strowmatt C., Latreille P., Miller N., Johnson D., Murray J., RA Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., RA Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., RA Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., RA Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E., RA Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E., RA Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A., RA Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A., RA Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R., RA McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H., RA Wilson R.K.; RT "The DNA sequence of human chromosome 7."; RL Nature 424:157-164(2003). RN [3] RP INVOLVEMENT IN HH16, AND FUNCTION. RX PubMed=22416012; DOI=10.1093/humrep/des022; RA Young J., Metay C., Bouligand J., Tou B., Francou B., Maione L., Tosca L., RA Sarfati J., Brioude F., Esteva B., Briand-Suleau A., Brisset S., RA Goossens M., Tachdjian G., Guiochon-Mantel A.; RT "SEMA3A deletion in a family with Kallmann syndrome validates the role of RT semaphorin 3A in human puberty and olfactory system development."; RL Hum. Reprod. 27:1460-1465(2012). RN [4] RP TISSUE SPECIFICITY. RX PubMed=28270793; DOI=10.3389/fneur.2017.00049; RA Lindholm T., Risling M., Carlstedt T., Hammarberg H., Wallquist W., RA Cullheim S., Skoeld M.K.; RT "Expression of Semaphorins, Neuropilins, VEGF, and Tenascins in Rat and RT Human Primary Sensory Neurons after a Dorsal Root Injury."; RL Front. Neurol. 8:49-49(2017). RN [5] RP VARIANT [LARGE SCALE ANALYSIS] THR-131. RX PubMed=16959974; DOI=10.1126/science.1133427; RA Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., RA Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., RA Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V., RA Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., RA Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., RA Velculescu V.E.; RT "The consensus coding sequences of human breast and colorectal cancers."; RL Science 314:268-274(2006). RN [6] RP VARIANT SER-396. RX PubMed=21248752; DOI=10.1038/nature09639; RA Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P., Davies H., RA Jones D., Lin M.L., Teague J., Bignell G., Butler A., Cho J., RA Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C., Jia M., RA Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A., Mudie L., RA Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S., Kahnoski R.J., RA Anema J., Tuveson D.A., Perez-Mancera P.A., Mustonen V., Fischer A., RA Adams D.J., Rust A., Chan-On W., Subimerb C., Dykema K., Furge K., RA Campbell P.J., Teh B.T., Stratton M.R., Futreal P.A.; RT "Exome sequencing identifies frequent mutation of the SWI/SNF complex gene RT PBRM1 in renal carcinoma."; RL Nature 469:539-542(2011). RN [7] RP VARIANTS HH16 TRP-66; SER-153; VAL-400; ILE-435; ALA-688; GLN-730 AND RP HIS-733, AND CHARACTERIZATION OF VARIANTS HH16 TRP-66; SER-153; VAL-400; RP ILE-435; ALA-688; GLN-730 AND HIS-733. RX PubMed=22927827; DOI=10.1371/journal.pgen.1002896; RA Hanchate N.K., Giacobini P., Lhuillier P., Parkash J., Espy C., RA Fouveaut C., Leroy C., Baron S., Campagne C., Vanacker C., Collier F., RA Cruaud C., Meyer V., Garcia-Pinero A., Dewailly D., Cortet-Rudelli C., RA Gersak K., Metz C., Chabrier G., Pugeat M., Young J., Hardelin J.P., RA Prevot V., Dode C.; RT "SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with RT Kallmann syndrome."; RL PLoS Genet. 8:E1002896-E1002896(2012). RN [8] RP VARIANTS HH16 TRP-66; ARG-82; SER-153; THR-342; ILE-435; GLY-447; TRP-484; RP MET-657 AND GLN-730. RX PubMed=25077900; DOI=10.1210/jc.2014-2110; RA Marcos S., Sarfati J., Leroy C., Fouveaut C., Parent P., Metz C., RA Wolczynski S., Gerard M., Bieth E., Kurtz F., Verier-Mine O., Perrin L., RA Archambeaud F., Cabrol S., Rodien P., Hove H., Prescott T., Lacombe D., RA Christin-Maitre S., Touraine P., Hieronimus S., Dewailly D., Young J., RA Pugeat M., Hardelin J.P., Dode C.; RT "The prevalence of CHD7 missense versus truncating mutations is higher in RT patients with Kallmann syndrome than in typical CHARGE patients."; RL J. Clin. Endocrinol. Metab. 99:E2138-2143(2014). CC -!- FUNCTION: Involved in the development of the olfactory system and in CC neuronal control of puberty. Induces the collapse and paralysis of CC neuronal growth cones. Could serve as a ligand that guides specific CC growth cones by a motility-inhibiting mechanism. Binds to the complex CC neuropilin-1/plexin-1. {ECO:0000269|PubMed:22416012}. CC -!- SUBUNIT: Interacts with PLXND1. {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: Secreted {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Expressed in the dorsal root ganglia. CC {ECO:0000269|PubMed:28270793}. CC -!- DOMAIN: Strong binding to neuropilin is mediated by the carboxy third CC of the protein. CC -!- DISEASE: Hypogonadotropic hypogonadism 16 with or without anosmia CC (HH16) [MIM:614897]: A disorder characterized by absent or incomplete CC sexual maturation by the age of 18 years, in conjunction with low CC levels of circulating gonadotropins and testosterone and no other CC abnormalities of the hypothalamic-pituitary axis. In some cases, it is CC associated with non-reproductive phenotypes, such as anosmia, cleft CC palate, and sensorineural hearing loss. Anosmia or hyposmia is related CC to the absence or hypoplasia of the olfactory bulbs and tracts. CC Hypogonadism is due to deficiency in gonadotropin-releasing hormone and CC probably results from a failure of embryonic migration of gonadotropin- CC releasing hormone-synthesizing neurons. In the presence of anosmia, CC idiopathic hypogonadotropic hypogonadism is referred to as Kallmann CC syndrome, whereas in the presence of a normal sense of smell, it has CC been termed normosmic idiopathic hypogonadotropic hypogonadism (nIHH). CC {ECO:0000269|PubMed:22416012, ECO:0000269|PubMed:22927827, CC ECO:0000269|PubMed:25077900}. Note=The disease may be caused by CC variants affecting distinct genetic loci, including the gene CC represented in this entry. CC -!- SIMILARITY: Belongs to the semaphorin family. {ECO:0000305}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; L26081; AAA65938.1; -; mRNA. DR EMBL; AC004451; AAS00353.1; -; Genomic_DNA. DR EMBL; AC004848; AAC78622.1; -; Genomic_DNA. DR CCDS; CCDS5599.1; -. DR PIR; D49423; D49423. DR RefSeq; NP_006071.1; NM_006080.2. DR RefSeq; XP_005250167.1; XM_005250110.3. DR RefSeq; XP_005250168.1; XM_005250111.4. DR RefSeq; XP_006715902.1; XM_006715839.3. DR RefSeq; XP_011514036.1; XM_011515734.2. DR RefSeq; XP_016867162.1; XM_017011673.1. DR AlphaFoldDB; Q14563; -. DR SMR; Q14563; -. DR BioGRID; 115650; 14. DR CORUM; Q14563; -. DR DIP; DIP-5744N; -. DR IntAct; Q14563; 1. DR MINT; Q14563; -. DR STRING; 9606.ENSP00000265362; -. DR GlyCosmos; Q14563; 4 sites, 2 glycans. DR GlyGen; Q14563; 4 sites, 2 O-linked glycans (1 site). DR iPTMnet; Q14563; -. DR PhosphoSitePlus; Q14563; -. DR BioMuta; SEMA3A; -. DR DMDM; 8134674; -. DR EPD; Q14563; -. DR jPOST; Q14563; -. DR MassIVE; Q14563; -. DR MaxQB; Q14563; -. DR PaxDb; 9606-ENSP00000265362; -. DR PeptideAtlas; Q14563; -. DR ProteomicsDB; 60045; -. DR Antibodypedia; 29608; 373 antibodies from 32 providers. DR DNASU; 10371; -. DR Ensembl; ENST00000265362.9; ENSP00000265362.3; ENSG00000075213.11. DR Ensembl; ENST00000436949.5; ENSP00000415260.1; ENSG00000075213.11. DR GeneID; 10371; -. DR KEGG; hsa:10371; -. DR MANE-Select; ENST00000265362.9; ENSP00000265362.3; NM_006080.3; NP_006071.1. DR UCSC; uc003uhz.4; human. DR AGR; HGNC:10723; -. DR CTD; 10371; -. DR DisGeNET; 10371; -. DR GeneCards; SEMA3A; -. DR GeneReviews; SEMA3A; -. DR HGNC; HGNC:10723; SEMA3A. DR HPA; ENSG00000075213; Tissue enhanced (retina). DR MalaCards; SEMA3A; -. DR MIM; 603961; gene. DR MIM; 614897; phenotype. DR neXtProt; NX_Q14563; -. DR OpenTargets; ENSG00000075213; -. DR Orphanet; 130; Brugada syndrome. DR Orphanet; 478; Kallmann syndrome. DR PharmGKB; PA35645; -. DR VEuPathDB; HostDB:ENSG00000075213; -. DR eggNOG; KOG3611; Eukaryota. DR GeneTree; ENSGT00940000158203; -. DR HOGENOM; CLU_009051_5_0_1; -. DR InParanoid; Q14563; -. DR OMA; TYLCHAV; -. DR OrthoDB; 5342713at2759; -. DR PhylomeDB; Q14563; -. DR TreeFam; TF316102; -. DR PathwayCommons; Q14563; -. DR Reactome; R-HSA-399954; Sema3A PAK dependent Axon repulsion. DR Reactome; R-HSA-399955; SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion. DR Reactome; R-HSA-399956; CRMPs in Sema3A signaling. DR SignaLink; Q14563; -. DR SIGNOR; Q14563; -. DR BioGRID-ORCS; 10371; 11 hits in 1156 CRISPR screens. DR ChiTaRS; SEMA3A; human. DR GeneWiki; SEMA3A; -. DR GenomeRNAi; 10371; -. DR Pharos; Q14563; Tbio. DR PRO; PR:Q14563; -. DR Proteomes; UP000005640; Chromosome 7. DR RNAct; Q14563; Protein. DR Bgee; ENSG00000075213; Expressed in stromal cell of endometrium and 129 other cell types or tissues. DR ExpressionAtlas; Q14563; baseline and differential. DR GO; GO:0030424; C:axon; IBA:GO_Central. DR GO; GO:0030425; C:dendrite; IEA:Ensembl. DR GO; GO:0005576; C:extracellular region; TAS:Reactome. DR GO; GO:0005615; C:extracellular space; IBA:GO_Central. DR GO; GO:0098978; C:glutamatergic synapse; IBA:GO_Central. DR GO; GO:0045499; F:chemorepellent activity; IBA:GO_Central. DR GO; GO:0038191; F:neuropilin binding; ISS:BHF-UCL. DR GO; GO:0030215; F:semaphorin receptor binding; IBA:GO_Central. DR GO; GO:0048846; P:axon extension involved in axon guidance; ISS:BHF-UCL. DR GO; GO:0007411; P:axon guidance; TAS:BHF-UCL. DR GO; GO:0060385; P:axonogenesis involved in innervation; ISS:BHF-UCL. DR GO; GO:0150020; P:basal dendrite arborization; ISS:ARUK-UCL. DR GO; GO:0021785; P:branchiomotor neuron axon guidance; ISS:ParkinsonsUK-UCL. DR GO; GO:0021612; P:facial nerve structural organization; ISS:ParkinsonsUK-UCL. DR GO; GO:0008045; P:motor neuron axon guidance; ISS:ParkinsonsUK-UCL. DR GO; GO:0050919; P:negative chemotaxis; IBA:GO_Central. DR GO; GO:0048843; P:negative regulation of axon extension involved in axon guidance; IBA:GO_Central. DR GO; GO:0010977; P:negative regulation of neuron projection development; IMP:ParkinsonsUK-UCL. DR GO; GO:0021675; P:nerve development; ISS:BHF-UCL. DR GO; GO:0001755; P:neural crest cell migration; IBA:GO_Central. DR GO; GO:1901166; P:neural crest cell migration involved in autonomic nervous system development; ISS:BHF-UCL. DR GO; GO:0001764; P:neuron migration; ISS:BHF-UCL. DR GO; GO:0021772; P:olfactory bulb development; IMP:UniProtKB. DR GO; GO:0046330; P:positive regulation of JNK cascade; TAS:ARUK-UCL. DR GO; GO:2001224; P:positive regulation of neuron migration; IBA:GO_Central. DR GO; GO:0048841; P:regulation of axon extension involved in axon guidance; IDA:UniProtKB. DR GO; GO:0071526; P:semaphorin-plexin signaling pathway; ISS:BHF-UCL. DR GO; GO:0048880; P:sensory system development; TAS:BHF-UCL. DR GO; GO:0061549; P:sympathetic ganglion development; ISS:BHF-UCL. DR GO; GO:0048485; P:sympathetic nervous system development; TAS:BHF-UCL. DR GO; GO:0097490; P:sympathetic neuron projection extension; ISS:BHF-UCL. DR GO; GO:0097491; P:sympathetic neuron projection guidance; ISS:BHF-UCL. DR GO; GO:0021637; P:trigeminal nerve structural organization; ISS:ParkinsonsUK-UCL. DR CDD; cd05871; Ig_Sema3; 1. DR CDD; cd11249; Sema_3A; 1. DR Gene3D; 2.60.40.10; Immunoglobulins; 1. DR Gene3D; 3.30.1680.10; ligand-binding face of the semaphorins, domain 2; 1. DR Gene3D; 2.130.10.10; YVTN repeat-like/Quinoprotein amine dehydrogenase; 1. DR InterPro; IPR007110; Ig-like_dom. DR InterPro; IPR036179; Ig-like_dom_sf. DR InterPro; IPR013783; Ig-like_fold. DR InterPro; IPR003599; Ig_sub. DR InterPro; IPR041416; IL-1RAcP-like_ig. DR InterPro; IPR016201; PSI. DR InterPro; IPR042820; Sema3A_sema. DR InterPro; IPR001627; Semap_dom. DR InterPro; IPR036352; Semap_dom_sf. DR InterPro; IPR027231; Semaphorin. DR InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf. DR PANTHER; PTHR11036; SEMAPHORIN; 1. DR PANTHER; PTHR11036:SF23; SEMAPHORIN-3A; 1. DR Pfam; PF18452; Ig_6; 1. DR Pfam; PF01403; Sema; 1. DR SMART; SM00409; IG; 1. DR SMART; SM00423; PSI; 1. DR SMART; SM00630; Sema; 1. DR SUPFAM; SSF48726; Immunoglobulin; 1. DR SUPFAM; SSF103575; Plexin repeat; 1. DR SUPFAM; SSF101912; Sema domain; 1. DR PROSITE; PS50835; IG_LIKE; 1. DR PROSITE; PS51004; SEMA; 1. DR Genevisible; Q14563; HS. PE 1: Evidence at protein level; KW Developmental protein; Differentiation; Disease variant; Disulfide bond; KW Glycoprotein; Hypogonadotropic hypogonadism; Immunoglobulin domain; KW Kallmann syndrome; Neurogenesis; Reference proteome; Secreted; Signal. FT SIGNAL 1..20 FT /evidence="ECO:0000255" FT CHAIN 21..771 FT /note="Semaphorin-3A" FT /id="PRO_0000032303" FT DOMAIN 31..514 FT /note="Sema" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00352" FT DOMAIN 580..664 FT /note="Ig-like C2-type" FT REGION 728..771 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 748..771 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 53 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 125 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 590 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT DISULFID 103..114 FT /evidence="ECO:0000250" FT DISULFID 132..141 FT /evidence="ECO:0000250" FT DISULFID 269..381 FT /evidence="ECO:0000250" FT DISULFID 293..341 FT /evidence="ECO:0000250" FT DISULFID 517..535 FT /evidence="ECO:0000250" FT DISULFID 649..722 FT /evidence="ECO:0000250" FT VARIANT 66 FT /note="R -> W (in HH16; phenotype consistent with Kallmann FT syndrome; dbSNP:rs199979628)" FT /evidence="ECO:0000269|PubMed:22927827, FT ECO:0000269|PubMed:25077900" FT /id="VAR_069200" FT VARIANT 82 FT /note="L -> R (in HH16; uncertain significance)" FT /evidence="ECO:0000269|PubMed:25077900" FT /id="VAR_072986" FT VARIANT 131 FT /note="A -> T (in a breast cancer sample; somatic mutation; FT dbSNP:rs143007146)" FT /evidence="ECO:0000269|PubMed:16959974" FT /id="VAR_036283" FT VARIANT 153 FT /note="N -> S (in HH16; phenotype consistent with Kallmann FT syndrome; dbSNP:rs139295139)" FT /evidence="ECO:0000269|PubMed:22927827, FT ECO:0000269|PubMed:25077900" FT /id="VAR_069201" FT VARIANT 342 FT /note="M -> T (in HH16; phenotype consistent with Kallmann FT syndrome)" FT /evidence="ECO:0000269|PubMed:25077900" FT /id="VAR_072987" FT VARIANT 396 FT /note="P -> S (found in a renal cell carcinoma sample; FT somatic mutation; dbSNP:rs866354226)" FT /evidence="ECO:0000269|PubMed:21248752" FT /id="VAR_064749" FT VARIANT 400 FT /note="I -> V (in HH16; phenotype consistent with Kallmann FT syndrome; digenic; found in a patient also carrying FT mutation Cys-268 in PROKR2; dbSNP:rs36026860)" FT /evidence="ECO:0000269|PubMed:22927827" FT /id="VAR_069202" FT VARIANT 435 FT /note="V -> I (in HH16; phenotype consistent with Kallmann FT syndrome; digenic; found in patients also carrying mutation FT Cys-268 in PROKR2 or mutation Arg-687 in FGFR1; FT dbSNP:rs147436181)" FT /evidence="ECO:0000269|PubMed:22927827, FT ECO:0000269|PubMed:25077900" FT /id="VAR_069203" FT VARIANT 447 FT /note="D -> G (in HH16; phenotype consistent with Kallmann FT syndrome; dbSNP:rs761486957)" FT /evidence="ECO:0000269|PubMed:25077900" FT /id="VAR_072988" FT VARIANT 484 FT /note="R -> W (in HH16; uncertain significance; FT dbSNP:rs137871935)" FT /evidence="ECO:0000269|PubMed:25077900" FT /id="VAR_072989" FT VARIANT 657 FT /note="I -> M (in HH16; phenotype consistent with Kallmann FT syndrome; dbSNP:rs748219597)" FT /evidence="ECO:0000269|PubMed:25077900" FT /id="VAR_072990" FT VARIANT 688 FT /note="T -> A (in HH16; phenotype consistent with Kallmann FT syndrome; digenic; found in a patient also carrying FT mutation Asp-217 in KAL1; dbSNP:rs318240751)" FT /evidence="ECO:0000269|PubMed:22927827" FT /id="VAR_069204" FT VARIANT 730 FT /note="R -> Q (in HH16; phenotype consistent with Kallmann FT syndrome; dbSNP:rs318240752)" FT /evidence="ECO:0000269|PubMed:22927827, FT ECO:0000269|PubMed:25077900" FT /id="VAR_069205" FT VARIANT 733 FT /note="R -> H (in HH16; phenotype consistent with Kallmann FT syndrome; dbSNP:rs318240753)" FT /evidence="ECO:0000269|PubMed:22927827" FT /id="VAR_069206" SQ SEQUENCE 771 AA; 88889 MW; 9985F8D3EAED8456 CRC64; MGWLTRIVCL FWGVLLTARA NYQNGKNNVP RLKLSYKEML ESNNVITFNG LANSSSYHTF LLDEERSRLY VGAKDHIFSF DLVNIKDFQK IVWPVSYTRR DECKWAGKDI LKECANFIKV LKAYNQTHLY ACGTGAFHPI CTYIEIGHHP EDNIFKLENS HFENGRGKSP YDPKLLTASL LIDGELYSGT AADFMGRDFA IFRTLGHHHP IRTEQHDSRW LNDPKFISAH LISESDNPED DKVYFFFREN AIDGEHSGKA THARIGQICK NDFGGHRSLV NKWTTFLKAR LICSVPGPNG IDTHFDELQD VFLMNFKDPK NPVVYGVFTT SSNIFKGSAV CMYSMSDVRR VFLGPYAHRD GPNYQWVPYQ GRVPYPRPGT CPSKTFGGFD STKDLPDDVI TFARSHPAMY NPVFPMNNRP IVIKTDVNYQ FTQIVVDRVD AEDGQYDVMF IGTDVGTVLK VVSIPKETWY DLEEVLLEEM TVFREPTAIS AMELSTKQQQ LYIGSTAGVA QLPLHRCDIY GKACAECCLA RDPYCAWDGS ACSRYFPTAK RRTRRQDIRN GDPLTHCSDL HHDNHHGHSP EERIIYGVEN SSTFLECSPK SQRALVYWQF QRRNEERKEE IRVDDHIIRT DQGLLLRSLQ QKDSGNYLCH AVEHGFIQTL LKVTLEVIDT EHLEELLHKD DDGDGSKTKE MSNSMTPSQK VWYRDFMQLI NHPNLNTMDE FCEQVWKRDR KQRRQRPGHT PGNSNKWKHL QENKKGRNRR THEFERAPRS V //